Dr. Amy Hartsfield is one of the only doctors in Alabama who has completed over 450 hours of Orofacial Pain and Dental Sleep Medicine. She continues to educate herself regularly on the latest techniques and clinical studies in Dental Sleep Medicine, Orofacial Pain, and headaches.
Lt. Colonel Theresa Long testifies before legistlators in Idaho.
LIVE from Nampa, Idaho, the Idaho Victims of Pandemic Policy & Law panel will discuss medical-related pandemic policy, biology, treatments, and misinformation. Stew Peters and a group of national experts will hold a listening event on the effects of the past two years on people’s lives, their professions, their health, their families, and a solution […]
The Journal of Insulin Resistance has published In a two-part research paper entitled “ Curing the pandemic of misinformation on COVID-19 mRNA vaccines through real evidence-based medicine,”
This was written by one of UK’s most eminent Cardiologists Dr. Aseem Malhotra, who was one of the first to take two doses of the vaccine and promote it on @Good Morning Britain says that since the rollout of the vaccine the evidence of its effectiveness and true rates of adverse events have changed.
Furthermore, real-world data reveals that in the non-elderly population, the number needed to vaccinate to prevent one death from Covid-19 runs into thousands and that re-analysis of randomized controlled trial data from the initial vaccine clinical trials suggests a greater risk of suffering a serious adverse event from the vaccine than to be hospitalized with Covid-19.
Listen to Concerned Doctors latest podcast below: As the new booster, or as the Biden administration calls it, the ‘updated vaccine’ rolled out with a glossy White House press conference in the past week, the obvious question is when do our public health authorities take an inventory of the good, bad and the downright deadly […]
September 12, 2022, President Biden signed the “Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe and Secure American Bioeconomy.”
Click Here to Enter Albert Benavides Dashboard
The Highwire with Del Bigtree The Highwire with Del Bigtree
In SARS-CoV-2-infected humans, disease progression is often associated with acute respiratory distress syndrome involving severe lung injury, coagulopathy, and thrombosis of the alveolar capillaries. The pathogenesis of these pulmonary complications in COVID-19 patients has not been elucidated. Autopsy study of these patients showed SARS-CoV-2 virions in pulmonary vessels and sequestrated leukocytes infiltrates associated with endotheliopathy and microvascular thrombosis. Since SARS-CoV-2 enters and infects target cells by binding its spike (S) protein to cellular angiotensin-converting enzyme 2 (ACE2), and there is evidence that vascular endothelial cells and neutrophils express ACE2, we investigated the effect of S-proteins and cell–cell communication on primary human lung microvascular endothelial cells (HLMEC) and neutrophils expression of thrombogenic factors and the potential mechanisms. Using S-proteins of two different SARS-CoV-2 variants (Wuhan and Delta), we demonstrate that exposure of HLMEC or neutrophils to S-proteins, co-culture of HLMEC exposed to S-proteins with non-exposed neutrophils, or co-culture of neutrophils exposed to S-proteins with non-exposed HLMEC induced transcriptional upregulation of tissue factor (TF), significantly increased the expression and secretion of factor (F)-V, thrombin, and fibrinogen and inhibited tissue factor pathway inhibitor (TFPI), the primary regulator of the extrinsic pathway of blood coagulation, in both cell types. Recombinant (r)TFPI and a thiol blocker (5,5′-dithio-bis-(2-nitrobenzoic acid)) prevented S-protein-induced expression and secretion of Factor-V, thrombin, and fibrinogen. Thrombomodulin blocked S-protein-induced expression and secretion of fibrinogen but had no effect on S-protein-induced expression of Factor-V or thrombin. These results suggests that following SARS-CoV-2 contact with the pulmonary endothelium or neutrophils and endothelial–neutrophil interactions, viral S-proteins induce coagulopathy via the TF pathway and mechanisms involving functional thiol groups. These findings suggest that using rTFPI and/or thiol-based drugs could be a viable therapeutic strategy against SARS-CoV-2-induced coagulopathy and thrombosis. View Full-Text
Politics is downstream from culture.